Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment
Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...
Clene announces evidence from post-hoc analysis of HEALY ALS platform trial
Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...
Supreme Court of Virginia Agrees to Hear Appian Petition to Reinstate $2.036 Billion Verdict Against Pegasystems, Inc.
Appian announced today that the Supreme Court of Virginia agreed to hear its petition seeking to reinstate the $2.036 billion ...